No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
PFE250117P40000
- 13.20
- -0.05-0.38%
15min DelayClose Jan 13 16:00 ET
13.30High13.20Low
13.30Open13.25Pre Close220 Volume448 Open Interest40.00Strike Price291.10KTurnover316.66%IV0.00%PremiumJan 17, 2025Expiry Date13.20Intrinsic Value100Multiplier3DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8772Delta0.0250Gamma1.97Leverage Ratio-0.2241Theta-0.0030Rho-1.72Eff Leverage0.0052Vega
Intraday
- 5D
- Daily
News
Market Chatter: Pfizer CEO Bourla Downplays Dispute With Activist Investor Starboard Value
Trump Looms Large Over Stock Markets. Why Chips, -2-
Express News | BioNTech SE - for 2025, Co & Pfizer Expect Largely Stable Vaccination Rates & Market Share in U.S. and Revenue Phasing Similar to 2024
Analysts Conflicted on These Healthcare Names: Xencor (XNCR) and Pfizer (PFE)
Pfizer (PFE) Receives a Hold From Citi
The CEO of Pfizer stated that they are "fully committed" to developing an experimental weight-loss drug.
On January 14, Glonghui reported that Albert Bourla, the CEO of the USA pharmaceutical company Pfizer, stated during the JPMorgan Medical Care Conference on Monday that the company is "fully committed" to developing its experimental weight loss drug and has been recruiting more experts in the field. Bourla mentioned that these experts are helping Pfizer make better and more rational decisions, and the company may begin late-stage research on its GLP-1R small molecule agonist Danuglipron in the second half of this year. After extensive experimentation, Pfizer expects to obtain data from the dosing study in a few months. With this drug.